PALOMA-3
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
PALOMA-3
Jun 23, 2024, 10:44 |
Blog
IV vs Subcutaneous amivantamab in EGFR NSCLC
Eric K. Singhi shared a post by Stephen V Liu, on X: "Absolutely agree with this! Compared with…
Jun 21, 2024, 13:43 |
Insight
Luca Dezzani: We are requesting approval from the U.S. FDA EGFR-mutated NSCLC therapy
Luca Dezzani, Vice President of US Oncology Medical Affairs at Johnson & Johnson, shared a…
Jun 13, 2024, 15:48 |
Insight
Stephen Liu on a paper by Natasha Leighl, et al.
Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…
Jun 8, 2024, 16:06 |
Blog
Reflections on ASCO24 by Jill Feldman
Jill Feldman shared on X/Twitter: "1. What an honor to meet Dr. Lynn Schuchter. I'm grateful…
Jun 1, 2024, 11:24 |
Blog
Narjust Florez: It is not only about living longer but also living well for our patients
Narjust Florez shared a post by Shankar Siva, Professor, Faculty of Medicine at University of Melbourne on…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube